Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Antidepressant

or [[:Category:Antivirals|Antiviral]]

Use the filters below to narrow your results.

None (2) · AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of phenytoin; sodium channel blocker (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releaser; sigma-1 agonist (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-000005D0-QINU`"' Selectivity comes from the viral-kinase-only initial phosphorylation step, which is why uninfected cells generate minimal active drug'"`UNIQ--ref-000005D1-QINU`"'. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV acyclovir. (1)

None (37) · 25 mg (1) · Initial genital herpes 1 g PO BID × 10 days; recurrent 500 mg BID × 3 days; suppression 500 mg-1 g PO daily; zoster 1 g TID × 7 days (1) · Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days (1) · Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days (1)

None (37) · 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 30, 45, 75 mg capsules; 6 mg/mL oral suspension (1) · 500 mg, 1 g tablets (1)

None (37) · 150 mg/d (treatment) (1) · 200 mg/d (1) · 3 g/d (zoster) (1) · Indication-specific; high-dose IV regimens for encephalitis or disseminated disease (1)

None (36) · IV (1) · Oral (5) · topical (1)

None (36) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Symptom relief within 24-48 hours (1) · Symptom relief within 24-48 hours of starting episodic treatment (1) · Symptom shortening detectable within 24-48 hours of starting (small absolute benefit; ~1 day reduction in symptom duration) (1)

None (36) · 12 hours (1) · 8 hours per dose (1) · 8 hours per oral dose (1) · Chronic daily dosing (1) · Long (1)

None (36) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~3 hours (acyclovir, the active metabolite); longer in renal impairment'"`UNIQ--ref-000005D6-QINU`"' (1) · ~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"' (1) · ~6-10 hours (oseltamivir carboxylate, the active metabolite)'"`UNIQ--ref-00000E94-QINU`"' (1)

None (36) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' (1) · ~50% (highly variable) (1) · ~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)'"`UNIQ--ref-000005D7-QINU`"' (1) · ~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"' (1)

None (36) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Generally used when influenza treatment is indicated; pregnancy is a recognized risk factor for severe influenza.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Widely used in pregnancy for HSV/VZV indications; reassuring registry data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Widely used in pregnancy when antiviral indicated; reassuring registry data.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (36) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (3)